Compare · KIDS vs RMD
KIDS vs RMD
Side-by-side comparison of OrthoPediatrics Corp. (KIDS) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KIDS and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $34.13B, about 53.4x KIDS ($639.7M).
- RMD has been more active in the news (9 items in the past 4 weeks vs 5 for KIDS).
- RMD has more recent analyst coverage (25 ratings vs 8 for KIDS).
- Company
- OrthoPediatrics Corp.
- ResMed Inc.
- Price
- -
- -
- Market cap
- $639.7M
- $34.13B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 5
- 9
- Recent ratings
- 8
- 25
OrthoPediatrics Corp.
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest KIDS
- OrthoPediatrics Announces Full Commercial Launch of 3P™ Pediatric Plating Platform® Hip System Following More Than 350 Successful Implantations
- SEC Form 10-Q filed by OrthoPediatrics Corp.
- OrthoPediatrics Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- OrthoPediatrics Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- OrthoPediatrics Corp. Reports Second Quarter 2026 Financial Results and Increases 2026 Financial Guidance
- OrthoPediatrics to Participate in the Canaccord Genuity 46th Annual Growth Conference
- OrthoPediatrics Corp. to Report Second Quarter Financial Results on August 4, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by OrthoPediatrics Corp.
- OrthoPediatrics Announces Distribution Agreement with OSSIO, Inc. to Provide Revolutionary Orthopedic Fixation Technology to U.S. Children’s Hospitals Nationwide
- Director Pelizzon David R was granted 11,436 shares, increasing direct ownership by 35% to 44,384 units (SEC Form 4)
Latest RMD
- 23XI Racing NASCAR Driver Tyler Reddick Reveals Sleep Apnea Diagnosis, Teams Up with Resmed to Help Others Recognize the Signs
- Rothschild & Co Redburn initiated coverage on ResMed with a new price target
- SEC Form 8-K filed by ResMed Inc.
- Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
- SEC Form 10-K filed by ResMed Inc.
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,026,596 worth of ResMed Common Stock (4,991 units at $205.69) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026
- Director Farrell Peter C sold $1,800,000 worth of ResMed Common Stock (8,000 units at $225.00) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 52,773 units (SEC Form 4)
- BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD)